Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.84
(-1.56%)
SEK 8.84
(-1.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 279.9 Million SEK | -5.9% |
| 2022 | 297.46 Million SEK | 7.66% |
| 2021 | 276.29 Million SEK | 31.32% |
| 2020 | 210.4 Million SEK | -17.16% |
| 2019 | 253.99 Million SEK | 27.0% |
| 2018 | 199.99 Million SEK | 29.26% |
| 2017 | 154.72 Million SEK | 14.98% |
| 2016 | 134.56 Million SEK | 5.98% |
| 2015 | 126.96 Million SEK | 15.47% |
| 2014 | 109.95 Million SEK | 17.95% |
| 2013 | 93.22 Million SEK | 23.42% |
| 2012 | 75.53 Million SEK | -4.37% |
| 2011 | 78.98 Million SEK | 4.55% |
| 2010 | 75.54 Million SEK | 55.85% |
| 2009 | 48.47 Million SEK | -8.79% |
| 2008 | 53.14 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 299.4 Million SEK | 6.97% |
| 2024 Q3 | 283.6 Million SEK | -7.5% |
| 2024 Q2 | 306.6 Million SEK | 2.4% |
| 2023 Q2 | 297.8 Million SEK | 0.37% |
| 2023 FY | 279.9 Million SEK | -5.9% |
| 2023 Q4 | 279.9 Million SEK | -6.7% |
| 2023 Q3 | 300 Million SEK | 0.74% |
| 2023 Q1 | 296.7 Million SEK | -0.26% |
| 2022 Q3 | 355.8 Million SEK | 7.66% |
| 2022 Q1 | 305.6 Million SEK | 10.61% |
| 2022 Q4 | 297.46 Million SEK | -16.4% |
| 2022 FY | 297.46 Million SEK | 7.66% |
| 2022 Q2 | 330.5 Million SEK | 8.15% |
| 2021 Q4 | 276.29 Million SEK | 3.4% |
| 2021 FY | 276.29 Million SEK | 31.32% |
| 2021 Q1 | 236.9 Million SEK | 12.59% |
| 2021 Q3 | 267.2 Million SEK | 1.56% |
| 2021 Q2 | 263.1 Million SEK | 11.06% |
| 2020 Q3 | 243.7 Million SEK | -8.86% |
| 2020 FY | 210.4 Million SEK | -17.16% |
| 2020 Q1 | 274.5 Million SEK | 8.07% |
| 2020 Q2 | 267.4 Million SEK | -2.59% |
| 2020 Q4 | 210.4 Million SEK | -13.66% |
| 2019 Q3 | 263.8 Million SEK | 5.1% |
| 2019 FY | 253.99 Million SEK | 27.0% |
| 2019 Q1 | 239.6 Million SEK | 19.8% |
| 2019 Q2 | 251 Million SEK | 4.76% |
| 2019 Q4 | 253.99 Million SEK | -3.72% |
| 2018 Q2 | 146.7 Million SEK | 2.59% |
| 2018 Q4 | 199.99 Million SEK | 46.41% |
| 2018 FY | 199.99 Million SEK | 29.26% |
| 2018 Q1 | 143 Million SEK | -7.58% |
| 2018 Q3 | 136.6 Million SEK | -6.88% |
| 2017 Q1 | 141.5 Million SEK | 5.15% |
| 2017 Q4 | 154.72 Million SEK | 4.54% |
| 2017 Q3 | 148 Million SEK | -3.08% |
| 2017 Q2 | 152.7 Million SEK | 7.92% |
| 2017 FY | 154.72 Million SEK | 14.98% |
| 2016 Q2 | 106.2 Million SEK | 17.61% |
| 2016 FY | 134.56 Million SEK | 5.98% |
| 2016 Q4 | 134.56 Million SEK | 13.66% |
| 2016 Q3 | 118.4 Million SEK | 11.49% |
| 2016 Q1 | 90.3 Million SEK | -28.88% |
| 2015 Q2 | 105.6 Million SEK | 1.93% |
| 2015 Q4 | 126.96 Million SEK | 22.56% |
| 2015 Q3 | 103.6 Million SEK | -1.89% |
| 2015 Q1 | 103.6 Million SEK | -5.78% |
| 2015 FY | 126.96 Million SEK | 15.47% |
| 2014 FY | 109.95 Million SEK | 17.95% |
| 2014 Q2 | 104.6 Million SEK | 22.2% |
| 2014 Q4 | 109.95 Million SEK | 0.79% |
| 2014 Q3 | 109.1 Million SEK | 4.3% |
| 2014 Q1 | 85.6 Million SEK | -8.18% |
| 2013 Q2 | 108.47 Million SEK | 27.29% |
| 2013 Q1 | 85.22 Million SEK | 12.82% |
| 2013 FY | 93.22 Million SEK | 23.42% |
| 2013 Q4 | 93.22 Million SEK | -2.4% |
| 2013 Q3 | 95.52 Million SEK | -11.94% |
| 2012 Q2 | 54.16 Million SEK | 10.46% |
| 2012 Q3 | 55.31 Million SEK | 2.12% |
| 2012 Q4 | 75.53 Million SEK | 36.55% |
| 2012 FY | 75.53 Million SEK | -4.37% |
| 2012 Q1 | 49.04 Million SEK | -37.91% |
| 2011 Q1 | 77.26 Million SEK | 2.28% |
| 2011 Q4 | 78.98 Million SEK | 7.35% |
| 2011 Q3 | 73.58 Million SEK | -21.64% |
| 2011 Q2 | 93.89 Million SEK | 21.52% |
| 2011 FY | 78.98 Million SEK | 4.55% |
| 2010 Q4 | 75.54 Million SEK | 0.0% |
| 2010 FY | 75.54 Million SEK | 55.85% |
| 2009 FY | 48.47 Million SEK | -8.79% |
| 2008 FY | 53.14 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -2445.008% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 89.533% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 89.533% |
| Arcoma AB | 33.3 Million SEK | -740.414% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 15.105% |
| BICO Group AB (publ) | 3.26 Billion SEK | 91.426% |
| CellaVision AB (publ) | 212.32 Million SEK | -31.827% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -1871.543% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -3974.865% |
| C-Rad AB (publ) | 122.4 Million SEK | -128.676% |
| Duearity AB (publ) | 17.53 Million SEK | -1496.691% |
| Dignitana AB (publ) | 37.56 Million SEK | -645.069% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -1313.636% |
| Getinge AB (publ) | 24.69 Billion SEK | 98.867% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -1258.718% |
| Iconovo AB (publ) | 14.55 Million SEK | -1823.197% |
| Integrum AB (publ) | 22.07 Million SEK | -1168.073% |
| Luxbright AB (publ) | 7 Million SEK | -3898.503% |
| Mentice AB (publ) | 163.55 Million SEK | -71.136% |
| OssDsign AB (publ) | 105.25 Million SEK | -165.921% |
| Paxman AB (publ) | 44.5 Million SEK | -528.862% |
| Promimic AB (publ) | 16.15 Million SEK | -1632.483% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -350.224% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -1215.443% |
| ScandiDos AB (publ) | 37.18 Million SEK | -652.703% |
| Sectra AB (publ) | 1.64 Billion SEK | 82.947% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -535.241% |
| Senzime AB (publ) | 58.06 Million SEK | -382.046% |
| SpectraCure AB (publ) | 14.97 Million SEK | -1769.115% |
| Stille AB | 172.64 Million SEK | -62.129% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 92.369% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | -11.707% |